Table 1.
Minimal inhibitory and bactericidal concentrations of 12 DHP-based HHQ derivatives against different antibiotic-resistant strains of H. pylori.
| DHP | MIC (MBC), mg/L | ||
|---|---|---|---|
| ATCC 700684 (CLR-R) | ATCC 43504 (MTZ-R) | Donostia 2 (LVX-R) | |
| MD1 | 8 (8) | 8 (8) | 8 (8) |
| MD2 | 8 (8) | 8 (8) | 4 (8) |
| MD3 | >64 (>64) | 64 (64) | 64 (64) |
| MD6 | 4 (4) | 4 (4) | 4 (4) |
| MD7 | 4 (4) | 4 (8) | 4 (8) |
| MD10 | 32 (64) | 32 (32) | 32 (64) |
| MD11 | 64 (64) | 64 (64) | 32 (64) |
| MD12 | >64 (>64) | >64 (>64) | >64 (>64) |
| MD13 | >64 (>64) | 64 (>64) | >64 (>64) |
| MD19 | 32 (32) | 64 (64) | 32 (64) |
| HM4 | 2 (2) | 2 (4) | 4 (4) |
| HM6 | 1 (1) | 2 (2) | 2 (2) |
| Clarithromycin | 16 (32) | <0.03 (<0.03) | <0.03 (<0.03) |
| Metronidazole | 1 (2) | 64 (128) | 8 (8) |
| Levofloxacin | 0.125 (0.125) | 0.5 (0.5) | 16 (32) |
MIC, minimal inhibitory concentration; MBC, minimal bactericidal concentration; CLR-R, clarithromycin-resistant strain; MTZ-R, metronidazole-resistant strain; and LVX-R, levofloxacin-resistant strain.